• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Incyte Corp.

    5/14/26 12:47:22 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $INCY alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)


    INCYTE CORPORATION

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)




    45337C102

    (CUSIP Number)
    03/31/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    45337C102


    1Names of Reporting Persons

    Dodge & Cox
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CALIFORNIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    11,646,204.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    12,252,356.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    12,252,356.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.2 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    INCYTE CORPORATION
    (b)Address of issuer's principal executive offices:

    1801 Augustine Cut-Off, Wilmington, DE 19803
    Item 2. 
    (a)Name of person filing:

    Dodge & Cox
    (b)Address or principal business office or, if none, residence:

    555 California Street 40th Floor, San Francisco, CA 94104
    (c)Citizenship:

    California, USA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    45337C102
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    12,252,356
    (b)Percent of class:

    6.2  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    11,646,204

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    12,252,356

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The clients of Dodge & Cox, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or power to direct the receipt of dividends from, and the proceeds from the sale of, INCYTE CORPORATION.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Dodge & Cox
     
    Signature:/S/ Katherine M. Primas
    Name/Title:Chief Compliance Officer
    Date:05/14/2026
    Get the next $INCY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INCY

    DatePrice TargetRatingAnalyst
    6/22/2026$94.00Underperform → Market Perform
    BMO Capital Markets
    5/22/2026$99.00Mkt Perform
    Bernstein
    3/16/2026$94.00Buy → Hold
    Jefferies
    2/5/2026$135.00Buy
    H.C. Wainwright
    1/20/2026$107.00Overweight → Equal Weight
    Wells Fargo
    12/8/2025$121.00Neutral → Outperform
    Mizuho
    11/3/2025$125.00Neutral → Buy
    Guggenheim
    10/8/2025Outperform → Perform
    Oppenheimer
    More analyst ratings

    $INCY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Principal Accounting Officer Tray Thomas was granted 2,834 shares, increasing direct ownership by 15% to 21,699 units (SEC Form 4)

    4 - INCYTE CORP (0000879169) (Issuer)

    7/20/26 4:10:36 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    CMO & Head of Late-Stage Dev. Stein Steven H sold $215,348 worth of shares (1,877 units at $114.73) and was granted 9,798 shares, increasing direct ownership by 34% to 30,916 units (SEC Form 4)

    4 - INCYTE CORP (0000879169) (Issuer)

    7/20/26 4:10:19 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    EVP & Chief Scientific Officer Mayes Patrick A was granted 5,916 shares, increasing direct ownership by 10% to 63,628 units (SEC Form 4)

    4 - INCYTE CORP (0000879169) (Issuer)

    7/20/26 4:10:01 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $INCY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for JAKAFI issued to INCYTE CORP

    Submission status for INCYTE CORP's drug JAKAFI (SUPPL-25) with active ingredient RUXOLITINIB PHOSPHATE has changed to 'Approval' on 09/27/2021. Application Category: NDA, Application Number: 202192, Application Classification: Labeling

    9/28/21 5:20:01 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    FDA Approval for JAKAFI issued to INCYTE CORP

    Submission status for INCYTE CORP's drug JAKAFI (SUPPL-23) with active ingredient RUXOLITINIB PHOSPHATE has changed to 'Approval' on 09/22/2021. Application Category: NDA, Application Number: 202192, Application Classification: Efficacy

    9/23/21 5:11:12 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    FDA Approval for OPZELURA issued to INCYTE CORP

    Submission status for INCYTE CORP's drug OPZELURA (ORIG-1) with active ingredient RUXOLITINIB has changed to 'Approval' on 09/21/2021. Application Category: NDA, Application Number: 215309, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated

    9/22/21 11:16:23 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $INCY
    SEC Filings

    View All

    Incyte Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - INCYTE CORP (0000879169) (Filer)

    7/6/26 4:06:20 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Incyte Corp. filed SEC Form 8-K: Other Events

    8-K - INCYTE CORP (0000879169) (Filer)

    6/22/26 7:00:40 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Incyte Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - INCYTE CORP (0000879169) (Filer)

    6/9/26 4:06:50 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $INCY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Incyte upgraded by BMO Capital Markets with a new price target

    BMO Capital Markets upgraded Incyte from Underperform to Market Perform and set a new price target of $94.00

    6/22/26 9:00:21 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Bernstein initiated coverage on Incyte with a new price target

    Bernstein initiated coverage of Incyte with a rating of Mkt Perform and set a new price target of $99.00

    5/22/26 8:40:19 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Incyte downgraded by Jefferies with a new price target

    Jefferies downgraded Incyte from Buy to Hold and set a new price target of $94.00

    3/16/26 8:35:28 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $INCY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology

    Agreement provides Incyte the rights to develop and commercialize ENHANZE® with its mutCALR development program and an option to nominate up to two additional targetsSAN DIEGO, July 20, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today announced that it has entered into a global collaboration and license agreement with Incyte (NASDAQ:INCY) to evaluate additional subcutaneous formulations of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs), utilizing Halozyme's proprietary ENHANZE® drug delivery technology. The collaboration will focu

    7/20/26 8:00:00 AM ET
    $HALO
    $INCY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch

    Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers

    Rapid oral presentations will highlight new Phase 1 data across Incyte’s solid tumor portfolio Both INCB161734, an investigational, potent, selective and orally bioavailable KRAS G12D inhibitor, and INCA338901, a TGFβR2×PD-1 bispecific antibody, are being evaluated in ongoing Phase 3 programs as first-line treatments for patients with advanced pancreatic ductal adenocarcinoma (PDAC) and microsatellite stable (MSS) colorectal cancer, respectively Incyte (NASDAQ:INCY) today announced that it will highlight data from several programs in its oncology portfolio in six presentations at the European Society of Medical Oncology (ESMO) Congress 2026, being held October 23 - 27, 2026, in Madr

    7/17/26 1:10:00 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types

    - Treatment with latarcibart led to an 81% median reduction in annualized bleeding rate (ABR) across all bleeding categories and patient types with von Willebrand disease (VWD) - Latarcibart, administered via a once monthly subcutaneous dosing regimen, was shown to be safe and well tolerated over multiple doses in this study - Pivotal Phase 3 VIVID-6 trial evaluating latarcibart’s potential to be the first targeted therapy for VWD is currently enrolling Incyte (NASDAQ:INCY) today announced complete safety and efficacy data from all patients (n=16) enrolled in the Phase 1/2 multidose study of VGA039 (latarcibart), a novel, Protein S-targeting, investigational monoclonal antibody for pa

    7/13/26 4:00:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $INCY
    Leadership Updates

    Live Leadership Updates

    View All

    Incyte Appoints Suketu (Suky) Upadhyay as Chief Financial Officer

    Incyte (NASDAQ:INCY) announces the appointment of Suketu (Suky) Upadhyay as Executive Vice President and Chief Financial Officer (CFO) effective May 4, 2026. In his new role, Mr. Upadhyay will serve as a key member of the Executive Leadership Team and lead the Company's global finance organization responsible for Strategic Financial Planning; Capital Allocation; Investor Relations; Finance, Planning and Accounting; Global Sourcing; Environmental, Social, and Governance; Information Technology and Facilities. "Suky will oversee all aspects of our finance function. He will guide our capital allocation approach and apply effective financial stewardship in support of value creation for our sh

    4/28/26 7:00:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales

    Mr. Taylor brings a strong track record launching multiple high-profile therapies, most recently serving as Senior Vice President, Sales at Arcutis Biotherapeutics (NASDAQ:ARQT), where he led U.S. sales efforts for ZORYVE®, a next-generation topical PDE4 inhibitor; previously, he held leadership roles at Incyte (NASDAQ:INCY) supporting the launch of OPZELURA® Mr. Taylor to lead Palvella's U.S. sales organization in preparation for the potential U.S. launch of QTORIN™ rapamycin for microcystic lymphatic malformations, a serious, rare, lifelong genetic disease affecting an estimated more than 30,000 diagnosed patients in the U.S. WAYNE, Pa., April 07, 2026 (GLOBE NEWSWIRE) -- Palvella Ther

    4/7/26 7:30:00 AM ET
    $ARQT
    $INCY
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch

    Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel

    Incyte (NASDAQ:INCY) announces the appointment of Richard Hoffman as Executive Vice President and General Counsel effective today, December 1, 2025. In his new role, Mr. Hoffman will serve as a key member of the Executive Leadership Team and be responsible for the Company's legal and compliance teams. "Richard joins us with a distinguished background, including many years of experience as a partner at a premier law firm, and a proven track record advising biopharma companies on corporate governance, strategic transactions, intellectual property and litigation," said Bill Meury, President and Chief Executive Officer, Incyte. "He possesses exceptional legal acumen and sound judgment to help

    12/1/25 8:00:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $INCY
    Financials

    Live finance-specific insights

    View All

    Incyte to Report Second Quarter Financial Results

    Incyte (NASDAQ:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 28, 2026. The schedule for the press release and conference call/webcast is as follows: Q2 2026 Press Release: July 28, 2026, at 7:00 a.m. ET Q2 2026 Conference Call: July 28, 2026, at 8:00 a.m. ET Domestic Dial-In Number: 877-407-3042 International Dial-In Number: 201-389-0864 Conference ID Number: 13759527 If you are unable to participate, a replay of the conference will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-612-

    7/8/26 8:00:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders

    - Proposed acquisition to add VGA039, a novel investigational monoclonal antibody that targets Protein S in Phase 3 development for von Willebrand disease (VWD) - Star Therapeutics to receive $1.25 billion upfront, with up to $750 million in additional payments upon achievement of sales milestones - Incyte will host an analyst and investor call on Monday, June 8, 2026, at 8:00 a.m. ET Incyte (NASDAQ:INCY) announced today it has entered into a definitive agreement to acquire Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics, LLC, for $1.25 billion. Star Therapeutics will be eligible to receive up to $750 million in additional payments upon the achievement of sales

    6/8/26 7:00:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates

    Total revenue of $1.27 billion and total net sales of $1.10 billion in the first quarter of 2026, an increase of 21% and 20% respectively, compared to the first quarter of 2025 Jakafi® (ruxolitinib) net sales of $758 million, an increase of 7% compared to the same period in 2025 Opzelura® (ruxolitinib) cream net sales of $143 million and Hematology and Oncology portfolio net sales of $204 million, an increase of 20% and 116%, respectively, compared to the first quarter of 2025 Four anticipated approvals and launches from mid-2026 into early 2027 Advanced povorcitinib development program, including the New Drug Application (NDA) acceptance in hidradenitis suppurativa (HS) and positiv

    4/28/26 7:00:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $INCY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Incyte Corp.

    SC 13G - INCYTE CORP (0000879169) (Subject)

    10/17/24 9:39:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: SEC Form SC 13D/A filed by Incyte Corp.

    SC 13D/A - INCYTE CORP (0000879169) (Subject)

    6/14/24 6:23:05 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13D/A filed by Incyte Corp. (Amendment)

    SC 13D/A - INCYTE CORP (0000879169) (Subject)

    5/13/24 6:06:33 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care